|
ROCKVILLE, Md., Jul 13, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report
financial results for second quarter 2010 on Thursday August 5, 2010,
after market close.
Company management will host a conference call at 5:00 pm Eastern on
August 5, 2010 to discuss the financial results for the second quarter
and first six months of 2010, recent business developments and the
forecast for 2010. The conference call will be accessible by dialing 888/713-4214
or 617/213-4866 (international) and providing passcode 93804688.
A webcast of the conference call will be accessible from the Company's
website at www.emergentbiosolutions.com,
under "Investors".
Emergent BioSolutions is offering call participants a pre-registration
option that expedites access to the call and minimizes hold times.
Pre-registrants will be issued a pin number to be used when dialing into
the live call which will provide quick access to the conference call by
bypassing the operator upon connection. Pre-registration, while not
mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PH6XLVE8Q
A replay of the conference call will be accessible, approximately one
hour following the conclusion of the call, by dialing 888/286-8010 or
617/801-6888 and using the passcode 16087459. The replay will be
available through August 19. The webcast will be archived on the
company's website, www.emergentbiosolutions.com,
under "Investors".
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax disease. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
BurrowsR@ebsi.com
or
Media:
Tracey Schmitt, 301-795-1800
Vice President, Corporate Communications
SchmittT@ebsi.com |